Home › Amgen drug fails to improve survival in multiple myeloma trial
 

Keywords :   


Amgen drug fails to improve survival in multiple myeloma trial

2014-08-14 03:55:33| Biotech - Topix.net

Amgen Inc's Kyprolis drug failed to extend survival compared to standard care in a trial involving patients with advanced multiple myeloma, a type of blood cancer that develops in the bone marrow.

Tags: improve multiple trial drug

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
06.10Glatfelter Develops Biobased Espresso Lid Material
06.10Tropical Storm Milton Potential Storm Surge Flooding Map
06.10Tropical Storm Milton Probabilistic Storm Surge Graphics
06.10Firms urge mayor to rethink congestion charge plan
06.10Tropical Storm Milton Public Advisory Number 5
06.10Summary for Tropical Storm Milton (AT4/AL142024)
06.10Tropical Storm Milton Graphics
06.10Tropical Storm Milton Graphics
More »